To estimate the frequency of headache in patients with confirmed COVID-19 and characterize the phenotype of headache attributed to COVID-19, comparing patients depending on the need of hospitalization and sex, an observational study was done. We systematically screened all eligible patients from a reference population of 261,431 between March 8 (first case) and April 11, 2020. A physician administered a survey assessing demographic and clinical data and the phenotype of the headache. During the study period, 2194 patients out of the population at risk were diagnosed with COVID-19. Headache was described by 514/2194 patients (23.4%, 95% CI 21.7–25.3%), including 383/1614 (23.7%) outpatients and 131/580 (22.6%) inpatients. The headache phenotype was studied in detail in 458 patients (mean age, 51 years; 72% female; prior history of headache, 49%). Headache was the most frequent first symptom of COVID-19. Median headache onset was within 24 h, median duration was 7 days and persisted after 1 month in 13% of patients. Pain was bilateral (80%), predominantly frontal (71%), with pressing quality (75%), of severe intensity. Systemic symptoms were present in 98% of patients. Headache frequency and phenotype was similar in patients with and without need for hospitalization and when comparing male and female patients, being more intense in females.Trial registration: This study was supported by the Institute of Health Carlos III (ISCIII), code 07.04.467804.74011 and Regional Health Administration, Gerencia Regional de Salud, Castilla y Leon (GRS: 2289/A/2020).

The ability of COVID-19 to compromise the respiratory system has generated a substantial proportion of critically ill patients in need of invasive mechanical ventilation (IMV). The objective of this paper was to analyze the prognostic ability of the pulse oximetry saturation/fraction of inspired oxygen ratio (SpO2/FiO2) and the ratio of SpO2/FiO2 to the respiratory rate–ROX index–as predictors of IMV in an emergency department in confirmed COVID-19 patients. A multicenter, retrospective cohort study was carried out in four provinces of Spain between March and November 2020. The discriminative power of the predictive variable was assessed through a prediction model trained using a derivation sub-cohort and evaluated by the area under the curve (AUC) of the receiver operating characteristic (ROC) on the validation sub-cohort. A total of 2040 patients were included in the study. The IMV rate was 10.1%, with an in-hospital mortality rate of 35.3%. The performance of the SpO2/FiO2 ratio was better than the ROX index–AUC = 0.801 (95% CI 0.746–0.855) and AUC = 0.725 (95% CI 0.652–0.798), respectively. In fact, a direct comparison between AUCs resulted in significant differences (p = 0.001). SpO2 to FiO2 ratio is a simple and promising non-invasive tool for predicting risk of IMV in patients infected with COVID-19, and it is realizable in emergency departments.

Objetivo. Derivar y validar una escala basada en variables recogidas durante la llamada a un centro coordinador de urgencias (CCU) que permita estratificar el riesgo de mortalidad a 2 días en pacientes con sospecha de enfermedad por COVID-19. Método. Estudio multicéntrico retrospectivo que incluyó a los pacientes consecutivos $ 18 años durante 3 meses, catalogados como caso sospechoso de COVID-19 después de la entrevista telefónica del CCU y que precisaron evacuación. Se analizaron variables clínico-epidemiológicas, comorbilidades y resultado de muerte a los 2 días. Se derivó una escala con las variables categóricas asociadas de forma independiente con la mortalidad a 2 días mediante regresión logística, en la cohorte de derivación. La escala se validó mediante una cohorte de validación y otra de revalidación obtenida en una provincia distinta. Resultados. Se incluyeron 2.320 pacientes (edad mediana 79 años, 49,8% mujeres). La mortalidad global fue del 22,6% (376 casos en pacientes con SARS-CoV-2). El modelo incluyó edad, localización (zona rural como variable protectora), institucionalización, desaturación, roncus, taquipnea y alteración del nivel de conciencia. El área bajo la curva (ABC) para la mortalidad a 2 días fue de 0,763 (IC 95%: 0,725-0,802; p < 0,001). La mortalidad en los pacientes de alto riesgo (> 2,4 puntos) fue del 60%. Conclusiones. La escala, derivada a través de información obtenida con datos del CCU, es aplicable a pacientes con sospecha de infección por COVID-19, estratifica el riesgo de mortalidad precoz (menos de 2 días) y puede ser una herramienta que ayude en la toma de decisiones, referidas a su evacuación, destino o vector de transporte.